PANTHERx Rare selected by Xeris Pharmaceuticals as Exclusive Distributor of Recorlev

PANTHERx Rare was recently selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole).

Recorlev is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Cushing’s syndrome, a disease associated with increased production of cortisol, occurs most commonly in adults between ages 30-50 and affects women two times more often than men.

Endogenous Cushing’s syndrome is a rare and serious endocrine disease, often the result of a benign pituitary tumor stimulating the body to overproduce cortisol for long periods of time, leading to unwanted physical and emotional symptoms.

Xeris Biopharma expects to launch Recorlev in the firsdt quarter of 2022 and has identified the addressable market of $2 billion in the U.S.

In 2011, PANTHERx embarked on a quest to reinvent specialty, revolutionize pharmacy, and redefine care. New orphan drug policies and advances in rare disease science set the stage for PANTHERx Rare to forge a new path and become a pharmacy focused on the needs of patients with rare, orphan, and devastating diseases.

The business model evolved so that the company was able to identify, define, and develop a RxARECARE™ program, reshaping specialty pharmacy: PANTHERx RARE.

Today, PANTHERx rare is the nation’s leading rare disease pharmacy. PANTHERx was the first pharmacy nationwide awarded the Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC).

Centene Corporation acquired PANTHERx in 2020. PANTHERx and its management team continue to operate independently as part of Centene’s Envolve Pharmacy Solutions.


Takeaway: PANTHERx streamlines the process associated with getting rare medications from the people who create them to the people who need them most, ultimately delivering better health outcomes to people living with rare diseases